In contrast, no antibody-based OA therapies have been developed against SP, despite strong experimental evidence supporting its role in neurogenic inflammation and nociception, and the therapeutic potential of targeting SP receptors in musculoskeletal diseases [38,70,71]. This evidence concerns the gene TFF2 and musculoskeletal system disorder.